Publication | Closed Access

HER-2 expression is a prognostic factor in patients with metastatic breast cancer treated with a combination of high-dose cyclophosphamide, mitoxantrone, paclitaxel and autologous blood stem cell support

Metastatic Breast CancerBreast OncologyHigh-dose CyclophosphamideMedicinePathologyBreast CancerCancer TreatmentRadiation OncologyOncologyCell BiologyTumor MicroenvironmentHer-2 ExpressionEndocrine-related Cancer